# SPACEGEN

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/spacegen

- Industry: Healthcare
- Headquarters: Xiamen, China
- Website: www.ispacegen.com
- Total disclosed funding: $6.1M
- Latest round: Series B (Sep 21, 2017)
- Investors on record: 3

## About

Established in 2015 and based in Xiamen, China, Xiamen SpaceGen Co., Ltd., trading as SPACEGEN, is a healthcare service provider which integrates R & D, production, sales and advisory services for cancer, genetic diseases and other personalized precision medical testing. It also provides solution products for early screening, disease diagnosis, individual drug selection and efficacy monitoring. In February 2026, Xiamen Spacegen Co., Ltd. raised Strategic Investment funding from new investor Shanghai Yinyu Investment Management Center and Autobio Diagnostics Co., Ltd.
The company independently develops more than 50 molecular-diagnostic products, including nearly 30 CE-IVD–approved kits (e.g., EGFR mutations, multi-gene oncology panels, endometrial-cancer classifiers). SPACEGEN provides NGS, real-time PCR, digital PCR, and nucleic-acid mass-spectrometry products, along with customized solutions for clinical institutions and research laboratories.
Revenue is generated to derive from sales of molecular-diagnostic kits, sequencing-workflow products, clinical testing services, and customized gene-detection solutions offered through its accredited labs. Additional income comes from international distribution, as its IVD portfolios are sold in 30+ countries and regions.

## Funding rounds

- Series B, Sep 21, 2017, $6.1M — Shanghai Jingxu Investment Center, Jingyuan Lanhai Venture Capital, Shanghai Dongfang Yirui Investment Management Co., Ltd.

## Investors

- Shanghai Jingxu Investment Center — Series B
- Jingyuan Lanhai Venture Capital (https://capitalatlas.ai/funds/jingyuan-lanhai-venture-capital) — Series B
- Shanghai Dongfang Yirui Investment Management Co., Ltd. — Series B